Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13305069 | 0.77 | — | — | |
| SCHEMBL291320 | 0.76 | — | — | |
| SCHEMBL15221558 | 0.76 | APLNR (0.32) | — | |
| SCHEMBL29452981 | 0.75 | — | — | |
| SCHEMBL9797853 | 0.74 | CCNB2 (0.33) | — | |
| SCHEMBL9961325 | 0.73 | LMNA (0.37) | LMNA | |
| SCHEMBL11032521 | 0.73 | — | — | |
| SCHEMBL17378974 | 0.71 | HDAC8 (0.32) | — | |
| SCHEMBL2009621 | 0.71 | ADORA2A (0.45) | — | |
| SCHEMBL1233375 | 0.71 | KDM4E (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1829709-A | Bicyclic imidazol derivatives against flaviviridae | GENELABS TECH INC (US) | 2006-09-06 | — | — | CN | claimed |
| US-20240199624-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CHDI FOUNDATION INC (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240182477-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. | 2024-06-06 | — | — | US | disclosed |
| WO-2024118607-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CHDI FOUNDATION, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| US-11912711-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2024-02-27 | — | — | US | disclosed |
| EP-3960737-B1 | BENZOCARBAZOLE-BASED COMPOUNDS AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING THEM | LG CHEMICAL LTD (KR) | 2023-08-09 | — | — | EP | disclosed |
| US-20230172057-A1 | HETEROCYCLIC COMPOUND CONTAINING HETEROATOM SUBSTITUTED FLUORENE AND OPTOELECTRONIC DEVICE | WUHAN TIANMA MICRO-ELECTRONICS CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| WO-2023275337-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-01-05 | — | — | WO | disclosed |
| WO-2023275333-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-01-05 | — | — | WO | disclosed |
| WO-2023275336-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-01-05 | — | — | WO | disclosed |
| EP-0985674-B1 | ORGANIC COMPOUNDS CONTAINING SILICON OR GERMANIUM, TRANSITION METAL COMPLEXES, CATALYST FOR ALPHA-OLEFIN POLYMERIZATION, AND PROCESSES FOR PRODUCING ALPHA-OLEFIN POLYMERS | MITSUBISHI CHEM CORP (JP) | 2003-04-23 | — | — | EP | disclosed |
| US-6255515-B1 | COORDINATION POLYMERIZATION CATALYSTS | MITSUBISHI CHEMICAL CORPORATION (JP) | 2001-07-03 | — | — | US | disclosed |
| EP-0985674-A1 | ORGANIC COMPOUNDS CONTAINING SILICON OR GERMANIUM, TRANSITION METAL COMPLEXES, CATALYST FOR $g(a)-OLEFIN POLYMERIZATION, AND PROCESSES FOR PRODUCING $g(a)-OLEFIN POLYMERS | MITSUBISHI CHEMICAL CORPORATION (JP) | 2000-03-15 | — | — | EP | disclosed |
| CN-1042395-C | Queen ant extrat oral liquid and its preparation method | KANGFU PHARMACEUTICAL CO LTD J (CN) | 1999-03-10 | — | — | CN | disclosed |
| CN-1091312-A | Queen ant extrat oral liquid and preparation method thereof | KANGFU PHARMACEUTICAL CO LTD J (CN) | 1994-08-31 | — | — | CN | disclosed |
| EP-0461145-A1 | MAGNESIUM FOLATES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | PANMEDICA S.A. (FR) | 1991-12-18 | — | — | EP | disclosed |
| US-5047405-A | Alzheimer*s disease | BIORESEARCH S.P.A. (IT) | 1991-09-10 | — | — | US | disclosed |
| WO-1990009382-A1 | MAGNESIUM FOLATES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | PANMEDICA (FR) | 1990-08-23 | — | — | WO | disclosed |
| US-4306064-A | Synthesis of 2,4-diamino-6-hydroxymethylpteridine | MONSANTO RESEARCH CORPORATION | 1981-12-15 | — | — | US | disclosed |
| US-4094874-A | Process for the production of 2-amino-4-hydroxy-6-methylpteridine | LONZA, LTD. (CH) | 1978-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172057-A1 | HETEROCYCLIC COMPOUND CONTAINING HETEROATOM SUBSTITUTED FLUORENE AND OPTOELECTRONIC DEVICE | CHRM1, CHRM2, CHRM4 | BCHE 3093/4885ACHE 2213/4885LMNA 2667/4885 |
| US-20240199624-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | MSH2, KRAS, CHAMP1 | BCHE 3744/4885ACHE 4492/4885LMNA 1270/4885 |
| US-20240182477-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | BCHE 1132/4885ACHE 570/4885LMNA 3558/4885 |
| US-11912711-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | BCHE 1132/4885ACHE 570/4885LMNA 3558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.